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Human cells and tissue products belong to a relatively new class of medical products. Therefore, limited
information is available on the classiﬁcation and premarket evaluation of human cells and tissue
products in the United States (US), the European Union (EU), and Japan. In this study, the deﬁnition,
legislation, and approval system of these products were surveyed. A total of nine autologous human cells
and tissue products approved until October 2013 were collected. The deﬁnitions of human cells and
tissue products were compatible among the US, the EU and Japan. The products were classiﬁed as human
cells, tissue, and cellular and tissue-based products (HCT/Ps) in the US, advanced therapy medicinal
products (ATMPs) in the EU, and cell/tissue-engineered products in Japan. These products were cate-
gorized as biologics and medical device in the US and Japan, and drug in the EU. The issuance of new
guidance induced regulatory impact for manufacturer, especially in the US. These products are subjected
to the accelerated approval of biological product, the humanitarian device exemption approval, the
premarket application approval, the biologics license application approval, and new drug application
approval with speciﬁc targeting of postapproval registry or surveillance. Of nine autologous human cells
and tissue products, four products had been evaluated using clinical experiences or open clinical trials
with small subjects, although the rests of products had been evaluated using comparative clinical trials
with control treatment. Our survey suggests that autologous human cells and tissue products would
need postmarket-oriented evaluation rather than premarket-oriented evaluation for doctors and
patients.
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tive Medicine. Production and hos1. Introduction
Regenerative medicine and tissue engineering are novel ways of
treating acute and chronic diseases and are expected to enable the
regeneration of tissue-speciﬁc functions. Because they are derived
from human cells and tissues, the products are regulated as bi-
ologics that differ signiﬁcantly from chemically synthesized drugs
[1]. Recently, human cells or tissues intended for implantation,
transplantation, infusion, or transfer into a human recipient have
been regulated as human cells, tissues, and cellular and tissue-
based products (HCT/Ps) in the United States (US) [2], somatic cell
therapy medicinal products or tissue-engineered products of
advanced therapy medicinal products (ATMPs) in the Europeanting by Elsevier B.V. All rights reserved.
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Although these innovative advanced products primarily belong to
the class of cell-based medical products for human use because
they contain or consist of living cells or tissues, the products have
two lateral aspects that allow them to be classiﬁed as drugs or
medical devices according to the primary mode of action [6] and to
be divided based on their origins as autologous and allogeneic
[2e5].
The deﬁnition of human cells and tissue products is similar but
deﬁnitely not the same among the US, the EU, and Japan. The
categorization or classiﬁcation of human cells and tissue products is
different among the US, the EU, and Japan [2e5].
The therapeutic areas of approved human cells and tissue
products vary from epidermal transplantation for emergency use
[7,8], ﬁbroblast injection for cosmetic surgical repair [9], trans-
plantation of tissue engineered cartilage [10e12], chondrocyte in-
jection for orthopedic trauma [10,11,13] to activated mononuclear
cell infusion for cancer treatment [14,15]. The premarket evaluation
of human cells and tissue products also varies, including the
accelerated approval [11], the humanitarian device exemption
(HDE) [7], the ATMP approval [10,12,15], and the premarket
approval [8e10,14].
However, few studies have been conducted to elucidate the
similarity or difference of the deﬁnition, category, premarket
approval evaluation by regulatory authorities, and adverse events
of human cells and tissue products. Recently, we have published the
regulation of allogeneic human cells and tissue products [16] that
are seven products on the market in the US only, and ﬁve of seven
products had evaluated using comparative clinical trials with
control treatment. Otherwise, there is no such detailed study of
autologous human cells and tissue products. In these products,
some products had been on the market as cell bank and the target
population of some indications such as orphan diseases is very
small. We developed a hypothesis about premarket approval
evaluation of autologous human cells and tissue products that may
be limited information, and may need a special market evaluation
system.
The aim of this study was to provide detailed information to
enhance the discussion regarding the regulatory approval of human
autologous cells and tissue products which have little consideration
about transplant graft rejection, and microbiological or viral
infections.
2. Materials and methods
This study included the autologous cells and tissue products in
the US, the EU or Japan by October 2013. The classiﬁcations and
deﬁnitions of the human cells and tissue products were different
among these two countries and the EU. In the US, the HCT/Ps
were deﬁned under sections 351 and 361 of the Public Health
Service (PHS) Act (42 the United State Code) according to Title 21,
Part 1271.10 and 1271.20 in the Code of Federal Regulation
(21CFR1271), respectively [2]. We focused on the HCT/Ps under
section 351 of the PHS Act which require premarket approval. The
HCT/Ps under section 361 were excluded due to the absence of a
requirement for premarket approval. The information on the
deﬁnition and classiﬁcation of HCT/Ps was obtained from the
Food and Drug Administration (FDA) website [2]. The information
on the approved HCT/Ps was obtained from the FDA website of
the approved cell therapy products [17] and the listing of the
Center for Devices and Radiological Health (CDRH) HDE [18]. The
information from the review reports for each HCT/P was obtained
from the appropriate FDA websites for Carticel™ [19], Epicel®
[20], Provenge® [21], and Laviv® [22]. In the EU, an ATMP is
deﬁned as a gene therapy medicinal product, a somatic celltherapy medicinal product, and a tissue-engineered product. We
focused only on ATMPs because of a similar deﬁnition for HCT/Ps
under section 351 of the PHS Act in the US. The information on
the deﬁnition and classiﬁcation of the ATMPs was obtained from
the European Medicine Agency (EMA) website [3]. The informa-
tion from the public assessment report for ChondroCelect® [23],
MACI [24], and Provenge [25] as AMTPs was obtained from the
EMA website because of central authorization. Although Glybera
(generic name: alipogene tiparvovec) was approved as the second
ATMP on October 25, 2012, in the EU [26], it was excepted from
this article because of allogeneic human cells and tissue product.
In Japan, the information on the deﬁnition and classiﬁcation of
cell/tissue-engineered products was obtained from the website of
the Ministry of Health, Labour and Welfare (MHLW) Legislation
Database, especially for Pharmaceutical and Food Safety Bureau
(PFSB) notiﬁcation No 0912006/2008 [4], and No 0208003/2008
[5]. The information from the review report for JACE [27] and
JACC [28] were obtained from the website of the Pharmaceuticals
and Medical Devices Agency (PMDA). The generic name and trade
name, cell origin, approval date, market authorization holder,
authority, indication and category of medicinal product for each
product were obtained from the regulatory information. The
history of regulatory action, preapproval and postapproval clin-
ical evaluation was obtained from the appropriate review reports
or public assessment reports.3. Results
3.1. Approved autologous cells and tissue products in the US, the EU,
and Japan
A total of nine approved autologous cells and tissue products in
the US, the EU, and Japan were on the market as of October 2013
(Table 1, Fig. 1). Four products derived from autologous chon-
drocytes for the repair of cartilaginous defects of the femoral
condyle were approved by the FDA, the EMA, and the MHLW in
Japan. Two products derived from autologous epidermis for use in
patients with deep dermal or full thickness burns (total body sur-
face area greater than or equal to 30%) were approved by the FDA
and the MHLW. Two products derived from autologous peripheral
blood mononuclear cells to treat hormone refractory prostate
cancer and a product from autologous ﬁbroblasts to improve the
appearance of nasolabial wrinkles were approved by the FDA and
the EMA.3.2. Classiﬁcation, deﬁnition, and regulation of human cells and
tissue products in the US, the EU, and Japan
The human cells and tissue products were classiﬁed and
deﬁned as HCT/Ps in the US, as ATMPs in the EU and as cell/
tissue-engineered products in Japan (Table 2). The approved
HCT/Ps were regulated under sections 351 of the PHS Act ac-
cording to 21CFR1271, which were categorized as drug or bio-
logical product or medical device. The approved AMTP was
regulated as the somatic cell therapy medicinal product and the
tissue engineering product under Regulation (EC) No 1394/2007
of the European Parliament and the Council of 13 November,
2007, which was categorized as medicinal product (drug). In
Japan, the approved cell/tissue-engineered products were regu-
lated as medical devices by adapting existing legislation under
clause 2 of the Pharmaceutical Affairs Law (PAL). The PFSB noti-
ﬁcation of No. 0280003/2008 describes the deﬁnition of cell/
tissue-engineered products, and the quality and safety of these
autologous products.
Table 1
Approved autologous human cells and tissue products in the US, EU, and Japan.
Generic name (trade
name)
Cell origin Approval date Marketing
authorization
holder
Authority Indication Category
US
Autologous cultured
chondrocytes
(Carticel™)
Autologous
chondrocytes
August 22, 1997 Genzyme Tissue
Repair, Cambridge,
MA, US
FDA/CBER Repair of clinically signiﬁcant, systematic,
cartilaginous defects of the femoral condyle
caused by acute or repetitive trauma.
In 2000, the indication has been changed to
narrow that “in patients who have had an
inadequate response to a prior arthroscopic or
other surgical repair procedure”.
Biologics
Cultured epidermal
autografts (Epicel®)
Autologous
epidermis
October 25, 2007 Genzyme
Biosurgery,
Cambridge, MA, US
FDA/CDRH Use in patients who have deep dermal or full
thickness burns comprising a total body surface
area of greater than or equal to 30%.
Medical
device
Sipuleucel-T
(Provenge®)
Autologous
peripheral
blood
mononuclear
cells
April 29, 2010 Dendreon Co.,
Seattle, WA, US
FDA/CBER Treatment of asymptomatic or minimally
symptomatic metastatic hormone refractory
prostate cancer.
Biologics
Azﬁcel-T (Laviv®) Autologous
ﬁbroblasts
June 21, 2011 Fibrocell Science
Inc., Boulder, CO, US
FDA/CBER Improvement of the appearance of moderate to
severe nasolabial fold wrinkles in adults.
Biologics
EU
Characterized viable
autologous cartilage
cells expanded
ex vivo expressing
speciﬁc marker
proteins
(ChondroCelect®)
Autologous
chondrocytes
October 5, 2009 Tigenix NV, Leuven,
Belgium
EMA/CHMP Repair of single symptomatic cartilaginous
defects of the femoral condyle of the knee (ICRS
grade III or IV) in adults.
ATMP
(Drug)
Matrix-applied
characterized
autologous cultured
chondrocytes (MACI)
Autologous
chondrocytes
June 27, 2013 Genzyme
Biosurgery ApS,
Kastrup, Denmark
EMA/CHMP Repair of symptomatic, full-thickness cartilage
defects of the knee (grade III and IV of the
Modiﬁed Outerbridge Scale) of 3e20 cm2 in
skeletally mature adult patients.
ATMP
(Drug)
Autologous peripheral-
blood mononuclear
cells activated with
prostatic acid
phosphatase
granulocyte-
macrophage colony-
stimulating factor
(Sipuleucel-T)
(Provenge)
Autologous
peripheral
blood
mononuclear
cells
September 6, 2013 Dendreon UK Ltd.,
London, UK
EMA/CHMP Treatment of asymptomatic or minimally
symptomatic metastatic (non-visceral) castrate
resistant prostate cancer in male adults in
whom chemotherapy is not yet clinically
indicated.
ATMP
(Drug)
Japan
Other surgical/
orthopedic
materials;
autologous cultured
epidermis (JACE)
Autologous
epidermis
October 29, 2007 Japan Tissue
Engineering Co.,
Ltd., Gamagori,
Japan
MHLW-PMDA/
OB
Use in patients with serious, extensive burns
when sufﬁcient donor sites for autologous skin
graft are not available and the total area of deep
dermal and full-thickness burns is 30% or the
total of surface area.
Medical
device
Human autologous cells
and tissues (JACC)
Autologous
chondrocytes
July 27, 2012 Japan Tissue
Engineering Co.,
Ltd., Gamagori,
Japan
MHLW-PMDA/
OB
An autologous cultured cartilage to alleviate
clinical symptoms by implanting it in the
affected site of traumatic cartilage deﬁciency
and osteochondritis dissecans (excluding knee
osteoarthritis) in the knee joints with a cartilage
defective area of 4 cm2 or more for which there
are no other options.
Medical
device
The US, the United States; The EU, the European Union; MA, Massachusetts; FDA, Food and Drug Administration; CBER, Center for Biologics Evaluation and Research; CDRH,
Center for Devices and Radiological Health; MHLW, Ministry of Health, Labour and Welfare; PMDA, Pharmaceuticals Medical Device Administration; OB, Ofﬁce of Biologics;
EMA, European Medicines Agency; CHMP, Committee for Human Medicinal Products; AMTP, Advanced Therapy Medicinal Products; WA, Washington; CO, Colorado; UK:
United Kingdom.
K. Yano et al. / Regenerative Therapy 1 (2015) 45e56 473.3. History of regulatory action, preapproval and postapproval
clinical evaluation of autologous human cells and tissues products in
the US, the EU, and Japan
In the US, prior to issuing of the guidance regarding manipu-
lated autologous structural (MAS) cells on May 28, 1996 [29], three
autologous human cells and tissues products such as Epicel®, Car-
ticel™ and Laviv® had been on the market from cell banks. After
issuing the guidance, Epicel® and Carticel™were submitted as BLA
and HDE, respectively in 1996. In compliance of FDA's regulation ofsomatic cell therapy, Laviv® was removed to ﬁle Investigation New
Drug Application (IND) in 1999 and BLA approval process. Pro-
venge® was submitted as IND to conduct clinical trials in 1996
(Fig. 1).
After being submitted as BLA in 1996, the product derived from
autologous chondrocytes, autologous cultured chondrocytes (Car-
ticel™, Genzyme Tissue Repair, Cambridge, MA, US) was approved
on August 22, 1997 for the accelerated approval of biological
products for serious or life-threating illnesses (21CFR601.40) [30]
using the Swedish clinical experience of 153 patients and the US
2005 201319951985 1990 2000 2010
Year
CarticelTM
Provenge®
Laviv®
Epicel®
US
Market prior to premarketing authorization
Market after premarketing authorization
Issuance of relevant regulation and guidance document
Files as HUD
Submitted premarket application 
Submitted IND or confirming application, or registered to Clinical Trial.gov
Conducting clinical trials
Regulatory reviewing 
JACE
Japan
JACC
ChondroCelect®
EU
Provenge 
MACI
Fig. 1. Pathway of approved autologous human cells and tissue products. In the US, as
the ﬁrst guidance regarding manipulated autologous structural (MAS) cells was issued
on May 28, 1996, three products such as Epicel®, Carticel™ and Laviv® had been on the
market. Carticel™was submitted as the biologics license application (BLA) in 1996, and
approved on August 22, 1997 for the accelerated approval of biological products for
serious or life-threating illness under 21CFR601.40. Epicel® was ﬁled as the humani-
tarian device exemption (HDE) application on February 5, 1997, designated as the
humanitarian use device (HUD) on November 30, 1998, and approved as the HDE on
October 25, 2007. Laviv® was submitted as the BLA on March 6, 2009 after completing
clinical trials under the investigational new drugs (IND) on October 12, 1999, and
approved as a biologic product on June 21, 2011. Provenge® was submitted to the IND
on December 22, 1996 and as the BLA on August 21, 2006 after completing clinical
trials, and approved as a biologic product on April 29, 2010. In Japan, after issuing of
the notiﬁcations with regard to medicinal products using human cells and tissues, JACE
was submitted to the new medical device application on October 6, 2004 using clinical
trial data collected after conﬁrming preclinical data, and approved as a new medical
device on October 29, 2007. JACC was submitted to the new medical device application
on August 24, 2009 using clinical trial data collected after conﬁrming preclinical data,
and approved as a new medical device on July 27, 2012. In the EU, after issuing the
Directive 2001/83/EC (medicinal products directive), the clinical trial of Chon-
droCelect® was conducted from 2002 to 2006. According to the Regulation (EC) 726/
2004 regarding to EU-wide marketing authorization, ChondroCelect® was submitted
through the centralized procedure on June 1, 2007, and approved as the ATMP on
October 5, 2009. Prior to the introduction of the Regulation (EC) 1394/2007, MACI was
available in certain European countries (i.e. Austria, Belgium, Denmark, Germany,
Greece, Ireland, Italy, The Netherlands, Norway, Portugal, Spain, and the United
Kingdom) and Australia, in accordance with national legislation since 1998. MACI was
submitted through the centralized procedure on September 1, 2011, and approved as
the ATMP on June 27, 2013. Provenge was submitted through the centralized procedure
on December 30, 2011, and approved as the ATMP on September 6, 2013.
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tion involved evidence such as functional outcomes compared with
literature, in the same patients, and histological ﬁnding on biopsy
that was judged to meet the standards for the accelerated approval
of biological products under 21CFR601.40. Under the accelerated
approval regulations, postapproval studies were required to
conﬁrm the long-term clinical beneﬁts including Randomized
clinical trial (RCT) with placebo, but due to the license holder's
request, the indication of Carticel™ has been approved to narrow to
second line therapy in 2000. Postapproval clinical studies,
including the registry-based study (RBS) of 97 US patients and the
study of the treatment of articular repair (STAR) of 154 patients
[31], were conducted to ensure the beneﬁt and safety of this
product (Table 3).
The product derived from autologous epidermis, cultured
epidermal autografts (Epicel®, Genzyme Biosurgery, Cambridge,
MA, US), was approved under the HDE on October 29, 2007 usingclinical experience data (552 patients from 1989 to 1996 and 734
patients from 1997 to 2006) and a physician-sponsored study of 44
patients after being designated as a humanitarian use device (HUD,
21CFR814.100) that was intended to beneﬁt patients by treating a
disease affecting fewer than 4000 individuals per year in the US
[32] (Table 3). Based on the preclinical and limited clinical data,
Epicel® had been judged that it would not expose patients to an
unreasonable risk or signiﬁcant risk of illness or injury, and the
probable beneﬁt to health from using the device would outweigh
the risk of illness or injury.
The product derived from autologous peripheral blood mono-
nuclear cells, Sipuleucel-T (Provenge®, Dendreon Co., Seattle, WA,
US), was approved on April 29, 2010 using the data from ﬁve clinical
trials with a total of 1026 patients. The pivotal study with 512 pa-
tients (Provenge®, 341 patients vs. Placebo, 171 patients) revealed
that the use of Provenge® prolonged overall survival (median 25.8
months) among men with metastatic castration-resistant prostate
cancer compared with the placebo (median 21.7 months). The
primary analysis showed a statistically signiﬁcant difference in
overall survival favoring Provenge® (p-value of 0.032) with hazard
ratio of death of 0.075 (95% CI: 0.614, 0.979) [33]. Currently, the
postapproval clinical study titled the registry of Sipuleucel-T ther-
apy in menwith advanced prostate cancer (PROCEED) is ongoing to
enroll 1500 patients (Table 3).
The product of autologous ﬁbroblasts, Azﬁcel-T (Laviv®, Fibro-
cell Science Inc., Boulder, CO, US), was approved on June 21, 2011
using the data from seven clinical trials with a total of 907 patients.
Two pivotal studies (IT-R-005 and IT-R-006) with total 421 patients
(Laviv®, 210 patients vs. vehicle-control, 211 patients) showed that
the co-primary endpoints of subject wrinkle assessment and
evaluator wrinkle assessment of Laviv® were statistically superior
to vehicle-control. The success rates for the evaluator wrinkle
assessment were 33% (33/100 patients) of Laviv® and 7% (7/103
patients) in IT-R-005, and 19% (21/110 patients) of Laviv® and 7%
(8/108 patients) in IT-R-006 [34] (Table 3). The FDA recommended
that a postmarket registry study should be conducted to access the
risk of skin cancer in the area of the Laviv® injection and immune-
mediated hypersensitivity reactions in 2700 subjects.
In the EU, the product of characterized viable autologous carti-
lage cells expanded ex vivo expressing speciﬁc marker proteins
(ChondroCelect®, Tigenix NV, Leuven, Belgium) were ﬁrst approved
as an ATMP on October 5, 2009 using the randomized, controlled
clinical trial data of 118 patients (ChondroCelect®, 57 patients vs.
microfracture, 61 patients) and the compassionate use data of 334
patients followed by pharmacovigilance. ChondroCelect® resulted
in better structural repair, as assessed by histmorphometry
(p ¼ 0.003) and overall histologic evaluation (p ¼ 0.0103) (Table 3).
Matrix-applied characterized autologous cultured chondrocytes
(MACI, Genzyme Biosurgery ApS, Kastrup, Denmark) consists of
autologous chondrocytes, seeded on a collagen membrane of
porcine origin (type I/III ACI-Maix) which is a CE marking device in
the EU. MACI is an ATMP deﬁned as combined tissue-engineering
product. Prior to the introduction of the Regulation (EC) 1394/
2007 and during the ATMP transitional period, MACI was available
in certain European countries (i.e. Austria, Belgium, Denmark,
Germany, Greece, Ireland, Italy, The Netherlands, Norway, Portugal,
Spain, and the United Kingdom) and Australia, in accordance with
national legislation since 1998. When Genzyme acquired the
Verigen Corporation in 2005, approximately 4000 patients in EU
and Australia had been treated with MACI. MACI was submitted
through the centralized procedure on September 1, 2011, and
approved as the ATMP on June 27, 2013 using the randomized,
controlled clinical trial data of 144 patients (MACI, 72 patients vs.
microfracture, 72 patients) and supportive data of approximately
800 patients from 19 studies with safety reports from postmarket
Table 2
Classiﬁcation, deﬁnition, and regulation of human cell and tissue products in the US, the EU, and Japan.
Country
or area
Classiﬁcation Deﬁnition Regulation
(notiﬁcation)
Classiﬁcation of
medical products
US Human cells, tissues and
cellular and tissue-based
products (HCT/Ps)
351HCT/Pa
361HCT/Pb
Articles containing or consisting of human cells or
tissues that are intended for implantation,
transplantation, infusion, or transfer into a human
recipient.
21CFR1271 Drug or biological
product or medical
device
EU Advanced therapy medicinal
products (ATMPs)
Gene therapy medicinal
productc
Somatic cell therapy medicinal
productc
Tissue engineered productc
Any of the following medicinal products for human use:
a gene therapy medicinal product; a somatic cell
therapy medicinal product; a tissue engineered product
which contains or consists of engineered cells or
tissues, and is presented as having properties for, or is
used in or administered to human beings with a view to
regenerating, repairing or replacing a human tissue.
Regulation (EC) No
1394/2007
Drug
Japan Cells/tissue-engineered
(manipulated) productsd
Drug or medical device containing or consisting of
manipulated autologous or allogeneic human cells and
tissue that are applying chemical treatment, alteration
of biological properties, combination by genetic
engineering to artiﬁcially proliferate or activate cells
and tissue for purpose of curing disease or repairing or
regenerating tissues.
NA (PFSB notiﬁcations
No. 0208003/2008 and
No. 0912006/2008)
Drug or medical
device
The US, the United States; The EU, the European Union; 21CFR, Code of Federal Regulation, title 21; NA, not available, EC, European Council; PFSB: Pharmaceutical and Food
Safety Bureau.
a 351HCT/P is regulated under sections 351 of the Public Health Service Act (42 the United State Code) according to in 21CFR1271.20 which is described as not meet the
criteria of 21CFR1271.10 and not qualify for any of the exception of 21CFR1271.15 which removed and implanted in same individual during same surgical procedure. The HCP/
P is regulated as drug, medical device, and/or biological product.
b 361HCT/P is regulated under sections 361 of the Public Health Service Act (42 the United State Code) which is described as minimally manipulated, intended for ho-
mologous use only, not involved the combination of cells or tissues with another article according to in 21CFR1271.10. No premarket approval is required.
c Gene therapy medicinal product, somatic cell therapy medical product, and tissue engineered product are regulated under the regulation (EC) No 1394/2007.
d Cells/tissue-engineered (manipulated) products are regulated as drug or medical device adapting existing legislation under the clause 2 of Pharmaceutical Affairs Law. The
PFSB notiﬁcations of No. 0280003/2008 for autologous product and No. 0912006/2008 for allogeneic product mentioned the deﬁnition of cells/Tissue-engineered products,
and the quality and safety of the products derived from human cells.
K. Yano et al. / Regenerative Therapy 1 (2015) 45e56 49experience. MACI was superior compared to standard care of
microfracture with symptomatic cartilage defects the knee with a
range of defect sizes from 3.0 to 20.0 cm2 (grade III and IV modiﬁed
outerbride scale), regarding mean improvement of pain and func-
tion (Table 3).
Autologous peripheral-blood mononuclear cells activated with
prostatic acid phosphatase granulocyte-macrophage colony-stim-
ulating factor (Sipuleucel-T) (Provenge, Dendreon UK Ltd., London,
UK) was submitted through the centralized procedure on
December 30, 2011, and approved as the ATMP on September 6,
2013 using the data from 14 clinical trials with a total of 1382 pa-
tients and post-market registry of 28 patients. The pivotal study
(IMPACT study) with 512 patients (Provenge®-arm, 341 patients vs.
Placebo-arm, 171 patients) be submitted to EMA was same data as
the FDA approved in 2010 (Table 3).
In Japan, a surgical/orthopedic material involving autologous
cultured epidermis (JACE, Japan Tissue Engineering Co., Ltd., Aichi,
Japan) was submitted as New Medical Device Application on
October 6, 2004, and was approved on October 29, 2007 using the
clinical trial data of two patients to conﬁrm the efﬁcacy and safety
of the product in the treatment of severe burns. Due to the
extremely limited number of patients in the clinical trial, the con-
ditions for approval were attached such as a postapproval clinical
trial with 30 patients and a postmarket survey for all patients
treated with JACE for seven years (Table 3).
Human autologous cells and tissues involving autologous
cultured chondrocytes (JACC, Japan Tissue Engineering Co., Ltd.,
Aichi, Japan) was submitted as New Medical Device Application on
August 24, 2009, and was approved on July 22, 2012 using the
clinical trial data of 32 patients to conﬁrm the efﬁcacy and safety of
the product in the treatment of traumatic cartilage deﬁciency and
osteochondritis. Due to the limited number of patients in the
clinical trial, the conditions for approval were attached such as apostmarket survey for all patients treated with JACE for seven years
(Table 3).
3.4. Regulatory pathways and legislation issuance
In the US, since the ﬁrst guidance on manipulated autologous
cells was issued in 1996 [29], many rules regarding HCTPs were
issued. In 1997, FDA proposed a new approach to the regulation of
HCTPs, which would establish in 21CFR1271 a comprehensive
regulatory program. Final rules of establishment registration and
listing in 2001, ﬁnal rules of donors eligibility as well as inspec-
tion and enforcement for current good tissue practice (CGTP) in
2004, and ﬁnal rules of donor screening, testing, and labeling in
2007 are the most important guidance for HCTPs regulations
(Table 4).
In the EU, the medicinal products directive was issued in 2001.
The regulation of medicinal products for human use regarding EU-
wide marketing authorization was issued in 2004 and ATMP
regulation was issued in 2007. According to ATMP regulation,
ATMP, other than tissue engineering products which were legally
on the EU market in accordance with national legislation on
December 30, 2008, shall be authorized using central application
no later than December 30, 2011. Tissue engineering products
which were legally on the EU market in accordance with national
legislation on December 30, 2008, shall be authorized using central
application no later than December 30, 2012 [3] (Table 4).
In Japan, a notiﬁcation for quality and safety assurance for
medical devices or drug products using cells or tissues was issued
in 1999 and the conﬁrming application prior to initiating clinical
trials had continued until 2011. In 2008, notiﬁcations for quality and
safety assurance for medical devices or drug products with pro-
cessed autologous and allogeneic human-derived cells and tissue
were issued [4,5](Table 4).
Table 3
History of regulatory action, preapproval and postapproval clinical evaluation of autologous human cells and tissue products in the US, the EU, and Japan.
Generic name (trade name) History of regulatory action Preapproval evaluation Postapproval evaluation
US
Autologous cultured
chondrocytes
(Carticel™)
 Began marketing in 1995 due to not to be
regulated for autologous cell therapy
 Submitted BLA in 1996
 Issued guidance regarding MAS cellsa on
May 28, 1996 (FDA determined to be
regulated)
 Approved on August 22, 1997 for accel-
erated approval
 Approval of narrow indication (second
line therapy) on March 2, 2000
Nonclinical studies
 Rabbit studies of improved healing at 52
weeks
 Dog study of improved healing at 13 and
26 weeks
Clinical studies
 Swedish Clinical Experience of 153 pa-
tients with retrospectively generated CRF
 US registry data of 191 patients repairing
of femoral condyle in 241 patients treated
Nonclinical studies
 Goat studies of histological healing at 16
weeks
 Horse study of histological healing at
eight weeks
Clinical studies
 Registry-based study (RBS) of 97 US pa-
tients in which 44 were part of subset of
191 patients in preapproval clinical
evaluation
 Study of the treatment of articular repair
(STAR) of 154 patients in which 136 and
115 patients were completed 24 and 48
months follow-up, respectively
Cultured epidermal
autografts (Epicel®)
 Commercialized from 1988 to 1996 as
banked human tissue
 Issued guidance regarding MAS cells on
May 28, 1996 (FDA determined to be
regulated)
 Filed as Humanitarian Device Exemption
(HDE) application on February 5, 1997
 Designated as Humanitarian Use Device
(HUD) on November 30, 1998
 Approved as HDE on October 25, 2007
Nonclinical studies
 In vitro and in vivo efﬁcacy studies
Clinical studies
 Clinical experience of 552 patients for
1989e1996 and 734 patients for 1997
e2006
 Physician-sponsored study of 44 patients
with and without Epicel® followed for
seven years
Nonclinical studies
 Not conducted
Clinical studies
 Not conducted
(No registry of ClinicalTrial.govb)
Sipuleucel-T (Provenge®)  Submitted IND on December 22, 1996
 Submitted BLA on August 21, 2006
 Approved as Biologic Products on April
29, 2010
Nonclinical studies
 In vitro study for PAPc expression in
human tissues
 Five in vivo studies for immunogenicity
and generation of PAP and efﬁcacy model
in mice and rats
 No toxicology studies
Clinical studies
 Randomized clinical trial (RCT) as pivotal
study of 512 patients to compare Pro-
venge® (341 patients) to placebo (171
patients)
 Other phase three, two RCTs of 225 pa-
tients to compare Provenge® (147 pa-
tients) to placebo (78 patients)
 Other phase three, a RCT of 176 patients
and phase two, an open-label trial of 113
patients
Nonclinical studies
 Not conducted
Clinical studies
 A Registry of Sipuleucel-T therapy in men
with advanced prostate cancer (PRO-
CEED)d of estimated enrollment 1500
patients, NCT01306890
Azﬁcel-T (Laviv®)  Marketed as cosmetic treatment from
December 1995 to February 1999
 Submitted IND on October 12, 1999
 Submitted BLA on March 6, 2009.
 Approved as Biologic Products on June 21,
2011
Nonclinical studies
 No preclinical studies conducted due to
applicable ﬁve published articles of
various in vitro and in vivo studies
Clinical studies
 Of 7 clinical trials, two randomized clin-
ical trial studies of phase 3 with 421 pa-
tients to compare Laviv® (210 patients) to
vehicle-control (211 patients) and phase
two an open-label trial of 50 patients
 Other indication for four trials of 436
patients
 Commercial experience of >9077 pa-
tients in the US and UK from 1995 to 2007
Nonclinical studies
 Not conducted
Clinical studies
 Proceeding pharmacovigilance activities
of estimated enrollment 2700 patients
(No registry of ClinicalTrial.govb website)
EU
Characterized viable
autologous cartilage cells
expanded ex vivo
expressing speciﬁc
marker proteins
(ChondroCelect®)
 Submitted through the centralized pro-
cedure on June 1, 2007
 Approved as ATMP on October 5, 2009
Nonclinical studies
 Goat study of improved repair at 52
weeks
 Single dose toxicity of nude mice and
sheep
 Carcinogenicity assay after serial
passaging
Clinical studies
 Randomized clinical trial of 144 patients
to compare ChondroCelect to
microfracture
 Compassionate use of 334 patients
Nonclinical studies
 Not conducted
Clinical studies
 Proceeding pharmacovigilance activities
(No registry of ClinicalTrial.govb and EU
Clinical Trials Registere website)
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Table 3 (continued )
Generic name (trade name) History of regulatory action Preapproval evaluation Postapproval evaluation
Matrix-applied
characterized autologous
cultured chondrocytes
(MACI)
 Available in certain European countries,
and Australia in accordance with national
legislations since 1998
 Submitted through the centralized pro-
cedure on September 1, 2011
 Approved as ATMP on June 27, 2013
Nonclinical studies
 Rabbit, sheep, and horse of repair at 53
weeks
 Single dose toxicity of mice and horse
 Chromosomal stability testing with lack
of tumorigenic ﬁndings
Clinical studies
 Randomized clinical trial of 144 patients
to compare MACI to microfracture
 Supportive data of approximately 800
patients from 19 studies
 Safety reports from post-market
experience
Nonclinical studies
 Not conducted
Clinical studies
 Proceeding pharmacovigilance activities
(5-year long term safety and efﬁcacy;
EudraCT: 2009-016970-33)
 Planned retrospective and prospective
study of pediatric patients
Autologous peripheral-
blood mononuclear cells
activated with prostatic
acid phosphatase
granulocyte-
macrophage colony-
stimulating
factor (Sipuleucel-T)
(Provenge)
 Submitted through the centralized pro-
cedure on December 30, 2011
 Approved as ATMP on September 6, 2013
Nonclinical studies
 In vitro study for PAPd expression in
human tissues
 Five in vivo studies for immunogenicity
and generation of PAP and efﬁcacy model
in mice and rats
 No toxicology studies
Clinical studies
 Randomized clinical trial (RCT) as pivotal
study of 512 patients to compare Pro-
venge (341 patients) to placebo (171
patients)
 Other phase three, two RCTs of 225 pa-
tients to compare Provenge (147 pa-
tients) to placebo (78 patients)
 Other phase three, a RCT of 175 patients,
and phase one and two, eight open-label
trials of 301 patients
 Two salvage studies of 169 patients
 Post-marketing experience of 28 patients
as of July 29, 2011 (PROCEED)
Nonclinical studies
 Not conducted
Clinical studies
 A Registry of Sipuleucel-T therapy in men
with advanced prostate cancer (PRO-
CEED)d of estimated enrollment 1500
patients, NCT01306890
 Proceeding phase 2 study with immuno-
suppressant therapies
 Proposed post-approval study and EU
registry study
Japan
Other surgical/orthopedic
materials; autologous
cultured epidermis
(JACE)
 Submitted New Medical Device Applica-
tion on October 6, 2004
 Approved as New Medical Device on
October 29, 2007
Nonclinical studies
 Biological safety studies
Clinical studies
 Clinical trial of two patients
Nonclinical studies
 Not conducted
Clinical studies
 Completed post-approval clinical trial
with 30 patients
 Proceeding post-market survey for all
patients treated with JACE for 7 years
Human autologous cells
and tissues
(JACC)
 Submitted conﬁrmatory application on
September 7, 2001 and conﬁrmed on
February 19, 2004
 Submitted New Medical Device Applica-
tion on August 24, 2009
 Approved as New Medical Device on July
22, 2012
Nonclinical studies
 Biological safety studies
 Rabbit and Dog studies for graft
treatments
Clinical studies
 Open clinical trial of 32 patients
 Follow-up study for safety after clinical
trial
Nonclinical studies
 Not conducted
Clinical studies
 Proceeding post-market survey for all
patients treated with JACC for 7 years
BLA, Biologics License Application; MAS, Manipulated Autologous; the FDA, the Food and Drug Administration; ND, Not determined; AMTP, Advanced Therapy Medicinal
Products; EU, European Union. IND, Investigational New Drug application; PAP, Prostatic acid phosphatase.
The US, The United State; The UK, The United Kingdom.
a US Food and Drug Administration. Guidance on application for products comprised of living autologous cells manipulated ex vivo and intended for structural repair or
reconstruction; availability. Fed. Regist. 61,26523e26254 (1996).
b http://clinicaltrials.gov/.
c PAP is an anigen expressed in prostate cancer tissue.
d http://clinicaltrials.gov/ct2/show/NCT01306890?term¼PROCEED&rank¼4.
e https://www.clinicaltrialsregister.eu/.
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tissue products for market authorization in the US, the EU, and
Japan demonstrated that the issuance of major regulations and
guidance, especially in the US, induced various market authoriza-
tions, such as the accelerated application approval, the HDE
approval, and the BLA (Fig. 1).3.5. Safety information: recalls, alters, notiﬁcation, and adverse
event reports
Recalls regarding two products were enforced three times
(Table 5). The Dear Healthcare Professional Letter from the manu-
facturer of Carticel™ was issued on March 2000, which was
Table 4
Major issuances of the legislation of human cells and tissue products in the US, the EU, and Japan.
Country or
area
Issuance
date
Name of legislation Note
US 1996 Guidance on application for Products Comprised of Living Autologous
Cells Manipulated Ex Vivo and Intended for Structure Repair or
Reconstruction; Availability
(Federal Register Vol. 61, No.103 P26523-26524, Notice May 28, 1996)
First guidance of manipulated autologous (MAS) cells
1997 Proposed Approach to Regulation of Cellular and Tissue-Based Products;
Availability and Public Meeting (Federal Register Vol. 62, No.42 P9721-
9722, Proposed Rules March 4, 1997)
Proposed rules of cellular and tissue-based products
2001 Human Cells, Tissues, and Cellular and Tissue-Based Products;
Establishment Registration and Listing (Federal Register Vol. 66, No.13
P5447-5469, Final Rules January 19, 2001)
Final rules of establishment registration and listing regarding
human cells, tissues and cellular and tissue-based products
(HCTPs)
2004 Eligibility Determination for Donors of Human Cells, Tissues, and
Cellular and Tissue-Based Products (Federal Register Vol. 69, No.101
P2978629834, Final Rule May 25, 2004)
Final rules of donors eligibility for HCTPs
Current Good Tissue Practice for Human Cells, Tissues, and Cellular and
Tissue-Based Product Establishment; Inspection and Enforcement
(Federal Register Vol. 69, No.226 P68612-68688, Final Rule November
24, 2004)
Final rules of inspection and enforcement for current good
tissue practice (CGTP) of HCTPs
2007 Human Cells, Tissues, and Cellular and Tissue-Based Products; Donor
Screening and Testing, and Related Labeling (Federal Register Vol. 72,
No.117 P33667-33669, Final rule June 19, 2007)
Final rules of donor screening and testing, and labeling for
HCTPs
EU 2001 Directive 2001/83/EC of the European Parliament and of the Council of 6
November 2001 on the Community code relating to medicinal products
for human use
Medicinal products directive regarding to GMP- and GCP-
compliance, advertising, labeling, classiﬁcation and distribution
2004 Regulation (EC) 726/2004 of the European Parliament and the Council of
31 March 2004 laying down Community procedures for the
authorization and supervision of medicinal products for human and
veterinary use and establishing a European Medicines Agency
Medicinal products for human use regarding to EU-wide
marketing authorization
2007 Regulation (EC) No 1394/2007 of the European Parliament and of the
Council of 13 November 2007 on advanced therapy medicinal products
and amending Directive 2001/83/EC and Regulation (EC) No 726/2004
Ofﬁcial Journal of the European Union (L324/121) Dec.10, 2007
Advanced therapy medicinal products (ATMP), ATMP deﬁnition,
ATMP complying with existing market authorization
requirements and the post-marketing pharmacovigilance rules,
a new Committee for Advanced Therapies (CAT)’s
responsibilities
2009 Commission Directive 2009/120/EC of 14 September 2009 amending
Directive 2001/83/EC of the European Parliament and of the Council on
the Community code relating to medicinal products for human use as
regards advanced therapy medicinal products
Commission Regulation (EC) No 668/2009 of 24 July 2009 implementing
Regulation (EC) No 1394/2007 of the European Parliament and of the
Council with regard to the evaluation and certiﬁcation of quality and
nonclinical data relating to advanced therapy medicinal products
developed by micro, small, medium-sized enterprises
Japan 1999 Quality and safety assurance for medical devices or drug products using
cells or tissues. (Iyakuhatsu: PFSB notiﬁcation No. 906 of July 30, 1999)
(in Japanese)
Conﬁrming application prior to initiating clinical trial. Records
and documents retention of speciﬁed biologics for 30 years and
biologics for 10 years
2000 Quality and safety assurance for drug products manufactured using
human- or animal-derived components as raw materials, Appendix 1:
Basic policies for handling and using drug products using cells and
tissue; Appendix 2: Guidance regarding quality and safety assurance for
drug products manufactured by processing human-derived cells and
tissue. (Iyakuhatsu: PFSB notiﬁcation No. 1314 of December 26, 2000)
(in Japanese)
Specifying notiﬁcation regarding quality and safety assurance
for drug products manufactured by processing human-derived
cells and tissue
2004 Guidance of regenerative medicine for epidermis using 3T3J2 and
3T3NIH as feeder cells with regard to guidance of infectious issues for
public health conducting xenotransplantation.(Iseikenhatsu: MHLW/
HPB/RDD notiﬁcation No. 0702001 of July 2, 2004) (in Japanese)
Notiﬁcation of regenerative medicine for epidermis using 3T3J2
and 3T3NIH as feeder cells
2008 Quality and safety assurance for drug products or medical devices with
processed (autologous) human-derived cells and tissue
(Yakushokuhatsu: MHLW/PFSB notiﬁcation No. 0208003 of February 8,
2008) (Partial amendment, Jimurenraku: Administrative notiﬁcation of
September 12, 2008) (in Japanese)
Notiﬁcation of drugs or medical devices with processed
autologous human-derived cells and tissue
Quality and safety assurance for drug products or medical devices with
processed (allogeneic) human-derived cells and tissue
(Yakushokuhatsu: MHLW/PFSB notiﬁcation No. 0912006 of September
12, 2008) (in Japanese)
Notiﬁcation of drugs or medical devices with processed
allogeneic human-derived cells and tissue
2010 Partial amendment with regard to quality and safety assurance for
medical devices or drug products using cells or tissues. (Yakushoku
hatsu: PFSB notiﬁcation No. 1101-3 of November 1, 2010) (in Japanese)
Exemption of conﬁrming application prior to initiating clinical
trial
The US: the United States; The EU: the European Union; MAS: Manipulated Autologous; HCTPs: Human Cells, Tissues and Cellular and Tissue-based Products; CGTP: Current
Good Tissue Practice; GMP: Good Manufacturing Practice; GCP: Good Clinical Practice; ATMP: Advanced Therapy Medicinal Products; CAT: Committee for Advanced Ther-
apies; MHLW: Ministry of Health, Labour and Welfare. PFSB: Pharmaceutical and Food Safety Bureau; HPB: Health Policy Bureau; RDD: Research and Development Division.
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Table 5
Recallsa of autologous human cells and tissue products in the US, the EU, and Japan.
Generic name
(Trade name)
Approval date Recall classb Date Reason Quantity
US
Autologous cultured chondrocytes
(Carticel™)
August 22, 1997 Class 2 May 17, 2006 Carticel™, possible contaminated with
Novosphingobium capsulatum, was distributed
1 lot
Class 2 September 1, 2010 Revised labeling of Carticel™ Essentials Kit
clariﬁes the non-sterile packing of the out clear
plastic tray which should not be opened in the
sterile ﬁelds
3132 kits
Cultured epidermal autografts (Epicel®) October 25, 2007 NA
Sipuleucel-T (Provenge®) April 29, 2010 Class 3 April 25, 2012 Provenge®, manufactured with a breach of
disposal collection kit, was distributed
1 unit
Azﬁcel-T (Laviv®) June 21, 2011 NA
EU
Characterized viable autologous
cartilage cells expanded ex vivo
expressing speciﬁc marker proteins
(ChondroCelect®)
October 5, 2009 NA
Matrix-applied characterized
autologous cultured chondrocytes
(MACI)
June 27, 2013 NA
Autologous peripheral-blood
mononuclear cells activated with
prostatic acid phosphatase
granulocyte-macrophage colony-
stimulating factor (Sipuleucel-T)
(Provenge)
September 6, 2013 NA
Japan
Other surgical/orthopedic materials;
autologous cultured epidermis
(JACE)
October 29,2007 NA
Human autologous cells and tissues
(JACC)
July 27, 2012 NA
NA: Not available.
Alerts and Notices (Devices): http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/default.htm.
Tips and Articles on Device Safety: http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/TipsandArticlesonDeviceSafety/default.htm.
List of Device Recalls: http://www.fda.gov/MedicalDevices/Safety/RecallsCorrectionsRemovals/ListofRecalls/default.htm.
Medical & Radiation Emitting Device Recalls: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRES/res.cfm.
Public Health Notiﬁcations: http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/PublicHealthNotiﬁcations/default.htm.
Medical Device Safety Communications: http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm181502.htm.
Recalls (Biologics): http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/Recalls/default.htm.
Enforcement Reports: http://www.fda.gov/Safety/Recalls/EnforcementReports/default.htm.
Online access to suspected side-effect reports: http://www.adrreports.eu/EN/index.html.
Product defects and recalls: http://www.ema.europa.eu/ema/index.jsp?curl¼pages/regulation/document_listing/document_listing_000238.jsp&mid¼WC0b01ac05800
24593.
Medical device recalls: http://www.info.pmda.go.jp/rsearch/html/menu_recall_base.html (in Japanese).
Medical device alters and notiﬁcations: http://www.info.pmda.go.jp/mdevices/md-others.html (in Japanese).
a A recall is an action taken to address a problem with a medical device that violates FDA law. Recalls occur when a medical device is defective, when it could be a risk to
health, or when it is both defective and a risk to health.
b Class 1 recall: a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or
death; Class 2 recall: a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the
probability of serious adverse health consequences is remote; Class 3 recall: a situation in which use of or exposure to a violative product is not likely to cause adverse health
consequences.
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adverse event reports regarding Epicel® from Manufacture and
User Device Experience (MAUDE) of the FDAwere 54 death reports,
seven other serious adverse events, and the rest of reports from
publication in the United Kingdom. Of 63 reports, three reports
mentioned that three serious adverse events as severe fever and
poor outcome were possibility of related to use the Epicel®. One
adverse event report for Carticel™ was voluntarily submitted as
high fever at one day after transplantation to MAUDE of the FDA. In
the EU and Japan, there was no recall and serious adverse event
report.
4. Discussion
Our ﬁndings show that there were various kinds of premarket
application approval for autologous human cells and tissueproducts, that the preapproval clinical evaluations were conducted
with small population or using clinical experience, while ﬁve of the
seven allogeneic human cells and tissue products were approved
for market authorization using relatively larger clinical trials
[36e40]. The results suggest that the products may lead to
postmarket-orientated evaluation rather than premarket-oriented
evaluation.
Our survey of nine autologous human cells and tissue products
approved by October 2013 shows that the deﬁnitions for human
cells and tissue products were deﬁnitely not same among the US,
the EU, and Japan, but still compatible for deﬁned products. In the
US, the distinction between HCT/Ps under sections 351 and 361 is
based on the degree of risk posed by the products: for low risk
products, so-called 361 products focus on minimizing the risk of
transmission of infectious diseases, and higher risk HCT/Ps, so-
called 351 products present in their processing or use. The 361
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function in the donor as recipient (homologous use), not be com-
bined with other agents and not have systemic affect [2]. Further-
more, the deﬁnition of ATMPs and cell/tissue-engineered products
in the EU and Japan, respectively, is easily understandable [3,5]. The
HCT/Ps under sections 351 and 361 of the PHS Act would be clas-
siﬁed as biological products under the control of the Center for
Biological Evaluation and Research (CBER) or as medical devices
under the control of the Center for Devices and Radiological Health
(CDRH) or drugs (currently not identiﬁed) in the US [2]. Two cell/
tissue-engineered products, JACE and JACC were classiﬁed as
medical devices rather than drugs, and regulated by the PFSB of
MHLW in Japan [5]. Otherwise, in the EU, ATMPs are classiﬁed as
drugs, and are regulated by the EMA [3], since medical devices are
applicable CE-marking which the manufacture declares that the
products conﬁrmwith the essential requirements of the applicable
EC directives. Actually, the human cells and tissue products that
were declared as medical devices using CE-marking prior to issuing
the Regulation (EC) No 1394/2007 [3] have been on the market,
which is only valid for selected member states in the EU. However,
these products have to be applied the ATMPs' rule for a centralized
authorization until end of 2012. Since the marketing authorization
of ChondroCelect®, three more ATMPs, Glybea, MACI, and Provenge
has been approved in the EU until as of October 2013. Both the US
and EU have already established sophisticated legislation, including
21CFR1271 [2], Regulation (EC) No 1394/2007 [3], Medical Products
Directive 2001/83/EC [41], and Regulation (EC) No 726/2004 [42]. In
contrast, Japan had adapted existing legislation under clause 2 of
the PAL [43,44]. Currently, in Japan, the revised PAL which is
changed the name of legislation as “Medicinal Products and Med-
ical Device Law” is reformed the category of human cells and tissue
products to “regenerative medicine products” [45].
A signiﬁcant regulatory impact occurred in 1996 in the US, when
the ﬁrst guidance of MAS cells was issued [29]. At that time, some
MAS cell products, including Epicel®, Carticel™ and Laviv®, were on
the market as banked human tissue (Fig. 1). Epicel® and Carticel™
were withdrawn from marketing in 1996 [19,20], and Laviv® in
1999 [46]. Depending on the primary mode of action and the
indication, the manufacturers can choose one of three different
premarket approval applications: the accelerated approval appli-
cation of biological products for serious or life-threating illness as
for Carticel™, the HUD designation and HDE approval application
as for Epicel®, and the IND application for conducting clinical trials
following BLA application as for Laviv® and Provenge®. In the EU, a
similar regulatory impact occurred in 2007, when the ATMP regu-
lation was issued [3]. At the time, MACI were available in certain
European countries and Australia in accordance with national
legislations since 1998 [24]. After receiving a several scientiﬁc ad-
vices from EMA's Committee for Medical Products for Human Use
(CHMP) and Committee for Advanced Therapies (CAT), MACI was
submitted through the centralized procedure on September 1, 2011,
and was approved as an ATMP on September 6, 2013. Otherwise,
both the products of JACE and JACC underwent newmedical device
approval applications [27,28], and ChondroCelect® and Provenge
went through the centralized applications for ATMPs [23,25] for
market authorization. These products might be applicable to the
fast track application for a life-threatening or chronically debili-
tating condition similar to that for an orphan drug and medical
device application to use in a small patient population, which is
50,000 patients in Japan [47] and no more than 5 in 10,000 people
in the EU at the time of submission of the rare disease (orphan)
designation application [48]. Furthermore, the accelerated approval
system of speciﬁcally targeted biological products for serious or
life-threating illnesses [30,49] should be focused on implementing
relevant regulation in the EU and Japan for fast application topatients. In Japan, the regulatory reform of medical products has
just implemented after the notice through ofﬁcial gazettes on
November 27, 2013. The new legislation will be available the
conditional/time-limited approval system for regenerative medi-
cine products [45].
For premarket approval authorization, safety and efﬁcacy data
from nonclinical and clinical studies are the most important in-
formation to be included for the examination of submitted docu-
ments or dossiers. In the present study, we focused on which
preapproval clinical evaluation had been conducted by the relevant
regulatory authorities. Clinical experience data [19,20] were used to
evaluate the safety of Epicel® and Carticel™ in the US, which were
on the market prior to their applications because these products
were distributed as banked human tissue. The data from two
pivotal trials with ﬁve supporting trials for Laviv® [22] were eval-
uated; however, nonclinical data were not submitted by the
sponsor because this product had been on the market as cosmetic
treatment for four years without FDA premarket approval, and
because an appropriate animal model for wrinkles was unavailable,
and much clinical information was available. As biologics and
ATMPs applications, the primary endpoints of Provenge® [21,25],
Laviv® [22], ChondroCelect® [23], and MACI [24] were evaluated.
These products were approved as an ATMP in the EU or as HCTPs in
the US, but no products have conﬁrmed the primary endpoint in
two clinical trials. According to the clinical reviewer's comments
from the clinical reviews of US FDA or public assessment report of
EMA, these products needed additional efﬁcacy information after
premarket approval because two clinical trials are typically
required to evaluate the primary endpoint in new drugs and bi-
ologics [22,23]. After premarket approval, postmarket registration
and surveillance have been conducted according to the condition of
approval: a postmarket clinical trial and surveillance of all patients
for seven years for JACE [27] and JACC [28], a 1500-patient registry
in US [21] and EU registry [25] for Provenge®, a 2700-patient reg-
istry for Laviv® [22], a postmarket safety and efﬁcacy study for
ChondroCelect® [23], and a postmarket safety and efﬁcacy study for
MACI [24]. During the postmarket surveillance, only three recalls
were enforced for Carticel™ and Provenge®. The FDA showed that a
total of 497 adverse events among 294 patients receiving Carticel™
were reported from 1996 to 2003 [50] and a serious adverse event
was voluntarily reported from user facility. Furthermore, 63 serious
adverse events for Epicel®were reported, while no serious adverse
event was reported on the other autologous human cells and tissue
products. Typical premarket-oriented evaluation is time-
consuming, expensive, and needs abundant human resources.
The advantages of postmarket-oriented review are easier access
than conducting clinical trial for patients, and would provide much
information on safety and efﬁcacy from a real world of clinical
experience and update safety information. Therefore, the latter
should be employed in some speciﬁc occasions such as orphan
disease and autologous human cells and tissue products. This
should be along the line with what is advocated in “Adaptive
licensing” [51]. We believe that adaptive licensing's character of
small population disease should ﬁt the autologous human cells and
tissue products, because the products are derived from autologous
cells and tissue and applied speciﬁc area such as unmet medical
needs which an ordinary drug or medical device do not enable to
cover. A similar approval system as adaptive licensing, the
conditional/time-limited approval system for regenerative medi-
cine products in Japan would accelerate the development of
regenerative medicine products.
For HCTPs, the FDA has focused on a risk-based approach to
examine the risks and beneﬁts [52]. In autologous HCT/Ps, it con-
siders three major hazards: donor infection and contamination
during processing or manufacturing, allergic reaction at the
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potential. The hazards are lessened by complying with the guidance
for donor eligibility [53] and current Good Tissue Practices [54].
Warnings and precautions regarding foreign materials, animal-
derived products, irritants and/or antibiotic use are described in
the labeling of Laviv® [55], JACE [56], JACC [57], Epicel® [58], and
MACI [59], and other information of ChondroCelect® [60], Provenge®
[61,62] and Carticel™ [63] is described in the product labeling.
Although the tumorigenic potential is believed rare, the possibility
cannot be completely excluded. Therefore, in vivo tumorigenicity
test using immunodeﬁcient mice was conducted in Epicel® [20],
JACE [27] and JACC [28]. The risk-based approach would be the best
way to develop a novel class product including human cells and
tissue products. Adaptive licensing [51] and the conditional/time-
limited approval system [45] should lessen the development
period and review time for human cells and tissue products.
There are limitations to this study. We examined nine autolo-
gous human cells and tissue products in the US, EU and Japan.
Whenmore than 20 products are approved, further study should be
conducted to compare the global evaluation system to determine
an efﬁcient and timely manner to deliver new product to patients.
Further analyses should compare the requirements of those prod-
ucts and the regulatory safety among the agencies, including
adverse reaction reporting such as the FDA MedWatch mandatory
reporting [64], EudraVigilance [65] and Postmarketing Safety [66],
during the postmarket surveillance because some of the premarket
clinical trials did not include a sufﬁcient patient population to be
clariﬁed the safety issues.
5. Conclusion
Autologous human cells and tissue products in the US, the EU
and Japan were approved for market authorization using various
kinds of premarket application system. The preapproval clinical
evaluations were conducted with small population or using clinical
experience, while most of allogeneic human cells and tissue
products were approved for market authorization using relatively
larger clinical trials. The clinical evaluation of the autologous hu-
man cells and tissue products would focus on postmarket-oriented
evaluation to distribute the new products of regenerative medicine,
tissue engineering, and cell therapy to patients and to oversee the
risk of these products using registry.
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